Biosimilar pills include erythropoietin, interferon, insulin, monoclonal antibodies (MABS), granulocyte colony stimulating elements and others. But, vaccines, plasma derived merchandise and their recombinant variations are excluded from the scope of this record. Furthermore, biologic capsules along with streptokinase and hyaluronidase are excluded from the observe due to the absence of right biosimilars recommendations. Patent expiry for reference biologics is placing the pace for the growth of biosimilars in this rather aggressive market. Recreating the patented protein structure for biosimilars is a key venture for regulators, as no two merchandise may be exactly the identical, which in addition complicates the regulatory procedure. Global biopharmaceutical regulators face numerous troubles bearing on the approval of biosimilars for numerous merchandise, because the regulations drafted for every product is precise to their method structure.
How Big is the Global Biosimilars Market?
The Global Biosimilars Market is expected to be around US$ 37.90 billion by 2028 and will grow at a CAGR of more than 26% in the given forecast period.
The major driving factors of Global Biosimilars Market are as follows:
The restraining factors of Global Biosimilars Market are as follows:
The Global Biosimilars Market is segmented on the lines of its product, application and regional. Based on product segmentation it covers recombinant nonglycosylated proteins, recombinant peptides and recombinant glycosylated proteins. Under application segmentation it covers oncology, blood disorders, growth hormone deficiency, chronic and sutoimmune diseases and infectious diseases. The Global biosimilars Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
This report provides:
1) An overview of the global market for Biosimilars and related technologies.
2) Analyses of global market trends, with data from 2019, estimates for 2020 and 2021, and projections of compound annual growth rates (CAGRs) through 2027.
3) Identifications of new market opportunities and targeted promotional plans for Global Biosimilars Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
REPORT SCOPE:
The scope of the report includes a detailed study of global and regional markets for Global Biosimilars Market with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Sandoz International GmbH (Germany), Hospira, Inc. (U.S.), and Teva Pharmaceutical Industries Ltd. (Israel), Dr. Reddy’s Laboratories (India), Biocon Limited (India), Mylan, Inc.(U.S.), Amgen (U.S.), Celltrion Inc. (South Korea), Roche Diagnostics (Switzerland), and Merck KGaA (Germany). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.
The Global Biosimilars Market has been segmented as below:
By Product Analysis
By Application Analysis
By Regional Analysis
Reasons to Buy this Report:
1) Obtain the most up to date information available on all Global Biosimilars Market.
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of Global Biosimilars Market data.
4) Assess your competitor’s refining portfolio and its evolution.
Customization:
We can offer you custom research reports as per client’s special requirements.
Below are our New Reports :-
1 INTRODUCTION
1.1 Key Take Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
2 Research Methodology
2.1 Secondary Data
2.1.1 Key Data From Secondary Sources
2.2 Primary Data
2.2.1 Key Data From Primary Sources
2.3 Biosimilars Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Biosimilars Market Breakdown & Data Triangulation
2.5 Assumptions for the Study
3 Executive Summary
3.1 Introduction
3.2 Conclusion
4 Premium Insights
4.1 Biosimilars: Market Overview
4.2 Geographic Analysis: Biosimilars Market, By Product
4.3 Biosimilars Market Size, By Application, 2018 vs 2024
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Incidences of Diseases
5.2.1.2 Increasing Demand for Biosimilar Drugs Due to Their Cost-Effectiveness
5.2.1.3 Growing Pressure to Curtail Healthcare Expenditure
5.2.1.4 Rising Geriatric Population
5.2.1.5 Strategic Collaborations Resulting in Enhanced Productivity and Clinical Trial Activities for Biosimilars
5.2.1.6 Increasing Government Support and Initiatives to Develop and Promote Biosimilars
5.2.2 Restraints
5.2.2.1 Complexities in Manufacturing and High Costs
5.2.2.2 Innovative Strategies By Biologic Drug Manufacturers
5.2.3 Opportunities
5.2.3.1 Emerging Markets
5.2.3.2 New Indications and Patent Expiry of Biologic Products
5.2.4 Challenge
5.2.4.1 Stringent Regulatory Requirements to Adversely Affect Investments in Biosimilars
5.3 Key Pipeline Products
5.4 Regulatory Outlook
5.4.1 North America
5.4.1.1 U.S.
5.4.1.2 Canada
5.4.2 Europe
5.4.3 Asia
5.4.3.1 China
5.4.3.2 India
5.4.3.3 Japan
5.4.3.4 South Korea
5.4.4 Rest of the World
5.4.4.1 Brazil
5.4.4.2 Mexico
5.4.4.3 Argentina
5.4.4.4 Saudi Arabia
5.5 Biosimilars Services Industry Insights
5.5.1 Introduction
5.5.2 Contract Manufacturing Organizations
5.5.3 Contract Research Organizations
5.5.4 Other Services (Nonclinical & Bioinformatics)
6 Biosimilars Market, By Type of Product
6.1 Introduction
6.2 Recombinant Non-Glycosylated Proteins
6.2.1 Insulin
6.2.2 Recombinant Human Growth Hormone (RHGH)
6.2.3 Granulocyte Colony-Stimulating Factor (Filgrastim)
6.2.4 Interferons
6.3 Recombinant Glycosylated Proteins
6.3.1 Erythropoietin (EPO)
6.3.2 Monoclonal Antibodies (MABS)
6.3.3 Follitropin
6.4 Recombinant Peptides
6.4.1 Glucagon
6.4.2 Calcitonin
7 Biosimilars Market, By Type of Manufacturing
7.1 Introduction
7.2 In-House Manufacturing
7.3 Contract Manufacturing Organizations
8 Biosimilars Market, By Application
8.1 Introduction
8.2 Oncology
8.3 Chronic and Autoimmune Diseases
8.4 Blood Disorders
8.5 Growth Hormone Deficiency
8.6 Infectious Diseases
8.7 Other Applications
9 Biosimilars Market, By Region
9.1 Introduction
9.2 North America Biosimilars Market
9.2.1 U.S.
9.2.2 Canada
9.3 Europe Biosimilars Market
9.3.1 Germany
9.3.2 France
9.3.3 U.K.
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Biosimilars Market
9.4.1 China
9.4.2 India
9.4.3 Japan
9.4.4 South Korea
9.4.5 Rest of Asia (RoA)
9.5 Rest of the World (RoW) Biosimilars Market
10 Competitive Landscape
10.1 Overview
10.2 Biosimilars Market Market Share Analysis
10.3 Competitive Situation and Trends
10.3.1 Regulatory Approvals
10.3.2 Agreements, Collaborations, and Partnerships
10.3.3 Product Launches
10.3.4 Acquisitions
10.3.5 Expansions
10.3.6 Other Developments
11 Company Profiles
11.1 Introduction
11.2 Pfizer Inc.
11.3 Sandoz International GmbH (A Division of Novartis International AG)
11.4 Teva Pharmaceutical Industries Ltd.
11.5 F. Hoffmann-La Roche Ltd.
11.6 Amgen Inc.
11.7 Biocon Ltd.
11.8 Dr. Reddy’s Laboratories
11.9 Celltrion Inc.
11.10 Mylan Inc.
11.11 Samsung Bioepis
The Global Biosimilars Market has been segmented as below:
By Product Analysis
By Application Analysis
By Regional Analysis
